Product Description
Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a616007.html)
Mechanisms of Action: ALK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belarus, Bosnia, Canada, China, Denmark, Egypt, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Kazakhstan, Korea, Mexico, North Macedonia, Poland, Portugal, Romania, Russia, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Large Cell Carcinoma|Large-Cell Anaplastic Lymphoma|Lymphoma|Lymphoproliferative Disorders|Neuroblastoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma
Phase 2: Bladder Cancer|Central Nervous System Cancer|Oncology Solid Tumor Unspecified|Primary Central Nervous System Lymphoma|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GO42286 | P2 |
Unknown Status |
Oncology Solid Tumor Unspecified |
2030-07-03 |
|
| DETERMINE | P3 |
Recruiting |
Neuroblastoma|Renal Cell Carcinoma|Large-Cell Anaplastic Lymphoma|Large Cell Carcinoma|Lymphoproliferative Disorders |
2029-10-01 |
|
| 2020-004239-25 | P2 |
Active, not recruiting |
Primary Central Nervous System Lymphoma|Central Nervous System Cancer |
2029-05-21 |
|
| BO40336 | P3 |
Unknown Status |
Non-Small-Cell Lung Cancer|Lymphoma |
2026-11-19 |